February 05, 2019
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Okogen begins phase 2 trial of adenoviral conjunctivitis treatment
Okogen has initiated a phase 2 clinical trial to evaluate the safety and efficacy of OKG-0301 for the treatment of acute adenoviral conjunctivitis.
OKG-0301 is a topical ophthalmic formulation of ranpirnase, which is a targeted ribonuclease with broad-spectrum antiviral properties that is found naturally in tears, according to a company press release.
The multicenter, randomized, placebo-controlled, double-masked RUBY trial will evaluate multiple doses of OKG-0301 in 219 adult patients with acute adenoviral conjunctivitis. Researchers will assess the treatment’s ability to reduce viral burden, safety and potential to diminish longer-term complications of adenoviral infection.
Adenoviral conjunctivitis does not have any approved treatments.